By proceeding, you agree to our Terms of Use and Privacy Policy.
Current guidelines call for screening for only five types of cancer, and in each case for one type of cancer per screen. This means that there are no screening tests available for the majority of cancers, and far too often cancer is only detected once it has reached a later stage with much lower prognosis and more difficult to treat compared to when cancer is detected earlier. Identification of tumors early, prior to metastasis and increased mutational burden, should translate to reduced mortality and morbidity, and early cancer detection, particularly for multiple cancers in a single non-invasive test, offers the potential for significant improvement in outcomes. But validating the impact of such tests requires considerable evaluation, and detection of early cancer signals in asymptomatic patients is much more challenging than looking for a specific type of cancer in patients at high risk for that cancer. Lengthy clinical trials may require fixing the algorithm for scoring results, whereas these tests are regularly being improved over time. Cost will also be important, and the most informative assays may involve multiple categories of biomarkers, which are likely to be more expensive than tests based on a single biomarker class. This program will examine and discuss both the opportunities and challenges in this rapidly changing field which has the potential to be highly disruptive of the current paradigm for cancer screening.
Check out the latest advancements and developments in early cancer surveillance.
Discover the latest developments in optimized biomarker testing, personalized medicine in cancer care, multi-cancer early detection, early cancer screening and more.
Uncover the latest advancements in high-risk patient screening, early cancer detection, and similar topics through insightful sessions and discussions.
Be motivated by inspirational speakers and learn more about the possible influence of early diagnosis on improving patient outcomes and cancer treatment.
Cambridge Healthtech Institute – Your Life Science Network Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations.
Merck Life Sciences is a leader in biomarker immunoassays, including 200+ MILLIPLEX® multiplex kits with over 1,200 different analytes, for use with Luminex® instrumentation, an ultra-high sensitivity platform for Single Molecule Counting (SMC™), inc
MISSION STATEMENT At Co-Diagnostics, we are passionate about providing the most robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications, especially to those regions
Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data.
BioFluidica® is a biotechnology company dedicated to eliminating obstacles to the adoption of liquid biopsy as a tool for researchers and clinicians.
Too many great product ideas never get made. Natech ensures our clients' innovative ideas are manufactured so they can get started on their next great idea.
STRATEC designs and manufactures fully automated analyzer systems, software and smart consumables for its partners in the fields of clinical diagnostics and life sciences.
ProPharma Group is the global, independent, single-source provider of regulatory and compliance consulting, clinical research services, pharmacovigilance, and medical information serving pharmaceutical, biotechnology, and medical device companies.
Burning Rock's laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification.
Primary.Health was born of a volunteer effort in a little California town to protect the health of one community, and we have grown into a company committed to protecting the health of every community through easy and affordable access to diagnostics
Primary.Health was born of a volunteer effort in a little California town to protect the health of one community, and we have grown into a company committed to protecting the health of every community through easy and affordable access to diagnostics.
Empowering healthcare professionals to reduce medication errors and improve patient care through access to the most trusted, evidence-based recommendations and education on drug therapy and medication management.
Zeon Specialty Materials, Inc. is a wholly owned subsidiary of ZEON CORPORATION of Tokyo, Japan, a world leader in specialty elastomers, polymers and specialty chemicals.
For over 50 years, Web Industries has been providing precision converting and outsource manufacturing services to innovative companies that make everything from the latest commercial airliners to juice boxes, network cables, and medical testing consu
For over 50 years, Web Industries has been providing precision converting and outsource manufacturing services to innovative companies that make everything from the latest commercial airliners to juice boxes, network cables, and medical testing consumables. Materials that we've slit, spooled, cut, o
Tasso is a fast-growing Seattle-based startup focused on delivering at-home diagnostic testing to those who need it most. We are growing our footprint with leading health systems, clinical research organizations, academic medical centers, and more wh
Tasso is a fast-growing Seattle-based startup focused on delivering at-home diagnostic testing to those who need it most. We are growing our footprint with leading health systems, clinical research organizations, academic medical centers, and more who are looking to deliver clinical-grade, convenien
Woodstock Sterile Solutions is a leading global provider of best-in-class sterile development and manufacturing solutions – with a decades-long track record of helping the healthcare companies advance molecules through clinical development into full-
Woodstock Sterile Solutions is a leading global provider of best-in-class sterile development and manufacturing solutions – with a decades-long track record of helping the healthcare companies advance molecules through clinical development into full-scale commercial production.
Avantor a Fortune 500 company is a leading global provider of mission-critical products and services to customers in the biopharma healthcare education & government and advanced technologies & applied materials industries. Our portfolio is used in vi
Avantor a Fortune 500 company is a leading global provider of mission-critical products and services to customers in the biopharma healthcare education & government and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.